KRTL Biotech Canada, Ltd.

KRTL CANADA Logo.png
  • “KRTL Biotech Canada” has a strategic purpose which encompasses many benefits but are not limited to:

  • Meeting Health Canada Government requirements for a Licensed Producer (LP) to operate “Health Canada Certified Facilities” to grow, processes and sell Cannabis along with Psilocybin and other plant-based products being legalized within the global “Psychotropic Drug Industry” now and in future

  • Conduct research & development with private entities, universities, therapeutic clinics, and hospitals

  • Obtain strategic development grants from both Federal & Provincial governments for research, clinical trials, and operations

  • KRTL Biotech Canada’s goal is to meet the required guidelines to become a Publicly Traded company in Canada as well as global stock exchanges

  • KRTL Biotech Canada will retain 100 percent ownership of its I.P. to better protect its formulas, products, and patents in Canada and Internationally.  All KRTL Biotech Canada I.P. is fully accessible by the KRTL Biotech International Group

  • KRTL Biotech Canada benefits from its strategic, geographical proximity in North America & Mexico utilizing the USMCA trade agreement, the Latin American Integration Association (ALADI), as well as easy access to E.U. Countries, Britain, and many others by maintaining “EU-GMP” Certification which is the most stringent classification globally   

  • This will allow KRTL Biotech Canada to collaborate jointly with R&D Development and clinical trials as well as cost effective locations for production, manufacturing, fulfillment & distribution

  • KRTL Biotech Canada will also partner and manage with therapeutic clinics, treatment centers and retreats it plans to develop for VIP clientele worldwide seeking treatment in exclusive, private therapeutic clinics located in natural, scenic settings worldwide

  • KRTL Biotech Canada has a medical and therapeutic focus on individual & group patients across all demographics, Indigenous Communities, Eldercare/Aging in Place, Military Veterans, Youth Organizations, Animal Sciences/Petcare, and many more for its therapeutic treatment facilities and products

  • Introduce and register Cannabis seeds to attain Health Canada government approval, creating a global KRTL CBD seed bank, including psychotropic and other plant-based medicinals, within the KRTL Biotech International Group affiliates and partners.   Bring opportunities to develop and distribute products within tariff free zones and through organizations such as USMCA Countries, Latin American Integration Association (ALADI), ASEAN Economic Community (AEC), European Union Members, BRICS, etc.

  • KRTL Biotech, Inc., the parent company, owns 49 percent of KRTL Biotech Canada and has authorized KRTL Biotech Canada exclusivity in Canada with the authority to negotiate favorable opportunities and contracts in conjunction with the KRTL Biotech International Group.